Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases
NCT ID: NCT00875147
Last Updated: 2016-10-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
163 participants
OBSERVATIONAL
2009-04-30
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases
NCT00779272
Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
NCT01493713
Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases
NCT02642185
Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets
NCT01632722
Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor
NCT01511146
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients, who underwent liver resection due to colorectal liver metastases after neoadjuvant chemotherapy, operated between 2005 and 2007 will be evaluated retrospectively. The patients will be distributed in two groups, either with or without bevacicumab. Outcome parameters are mortality, complications, hospital stay and ICU stay. To increase the power of the study the total number of patients will be increased by adding patients from other centers. Results will be adjusted for the propensity of developing complications.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
with bevacizumab
Neoadjuvant chemotherapy with bevacizumab
bevacizumab
Neoadjuvant chemotherapy with bevacizumab
without Bevacizumab
Neoadjuvant chemotherapy without Bevacizumab
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bevacizumab
Neoadjuvant chemotherapy with bevacizumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ksenija Slankamenac
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefan Breitenstein, MD
Role: PRINCIPAL_INVESTIGATOR
Departement of Visceral and Transplantation Surgery of University hospital of Zurich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de Chirurgie Viscérale et de Transplantation, Hautepierre Hospital
Strasbourg, Strasbourg, France
Division of hepato-biliary-pancreatic surgery. Department of surgery, "Josep Tureta" Hospital
Girona, Girona, Spain
University Hospital of Zurich
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
StV 12-2009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.